Literature DB >> 21426228

Food and Drug Administration recommends against the continued use of propoxyphene.

.   

Abstract

Following receipt of a Citizens' petition, the Food and Drug Administration (FDA) convened an advisory committee to address the safety of propoxyphene. This led to a comprehensive review that culminated in a November 19, 2910, press release in which the FDA recommended against continued use of the drug. The FDA release contains a data summary (background), a safety announcement, additional Information for Patients, additional information for health care professionals, and references. All dosage forms of the drug have now been withdrawn from the United States market.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21426228     DOI: 10.3109/15360288.2010.549553

Source DB:  PubMed          Journal:  J Pain Palliat Care Pharmacother        ISSN: 1536-0288


  8 in total

1.  Rise and fall of anti-obesity drugs.

Authors:  Ming-Fang Li; Bernard My Cheung
Journal:  World J Diabetes       Date:  2011-02-15

2.  The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation.

Authors:  Gary A Gintant; David J Gallacher; Michael K Pugsley
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.

Authors:  David Kao; Becki Bucher Bartelson; Vaishali Khatri; Richard Dart; Philip S Mehler; David Katz; Mori J Krantz
Journal:  Ann Intern Med       Date:  2013-05-21       Impact factor: 25.391

4.  The influence of propoxyphene withdrawal on opioid use in veterans.

Authors:  Corey J Hayes; Teresa J Hudson; Martha M Phillips; Zoran Bursac; James S Williams; Mark A Austin; Mark J Edlund; Bradley C Martin
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-08-06       Impact factor: 2.890

5.  Treatment of obesity in children and adolescents.

Authors:  Kelly L Matson; Renee M Fallon
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 6.  Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.

Authors:  Arthur N Westover; Ethan A Halm
Journal:  BMC Cardiovasc Disord       Date:  2012-06-09       Impact factor: 2.298

7.  Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events.

Authors:  Molly M Jeffery; Nancy E Morden; Marc Larochelle; Nilay D Shah; W Michael Hooten; Ellen Meara
Journal:  Med Care       Date:  2020-01       Impact factor: 3.178

8.  Use of analgesics in France, following dextropropoxyphene withdrawal.

Authors:  E Van Ganse; M Belhassen; M Ginoux; E Chrétien; C Cornu; C Ecoffey; F Aubrun
Journal:  BMC Health Serv Res       Date:  2018-04-02       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.